Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia-Reference-Cited by-同舟云学术

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

Published:2009-04-30 Issue:9 Volume:23 Page:1537-1544
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Cortes J E,Egorin M J,Guilhot F,Molimard M,Mahon F-X

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200988.pdf

Reference57 articles.

1. Goldman JM, Melo JV . Chronic myeloid leukemia—advances in biology and new approaches to treatment. New Engl J Med 2003; 349: 1451–1464.

2. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

3. O'Dwyer M . Multifaceted approach to the treatment of bcr-abl positive leukemias. Oncologist 2002; 7: 30–38.

4. Melo JV, Barnes DJ . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441–453.

5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia;Annals of Hematology;2024-06-07

2. Beyond IC₅₀- A computational dynamic model of drug resistance in enzyme inhibition treatment;2024-03-26

3. Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients;Cancer Chemotherapy and Pharmacology;2024-03-05

4. Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China;Therapeutic Advances in Hematology;2024-01

5. Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19;European Journal of Pharmaceutical Sciences;2023-05